Symptomatic Cardiac Events in Patients with Lung Tumors Near The Heart Treated with Stereotactic Ablative Radiotherapy (SABR): A Single Institution Experience

被引:0
|
作者
Ko, R. B. [1 ]
Jani, K. [2 ]
Sodji, Q. [2 ]
Merriott, D. J. [3 ]
Pickthorn, W. [2 ]
Bush, K. [1 ]
Maxim, P. G. [4 ]
Diehn, M. [5 ]
Loo, B. W., Jr. [1 ]
机构
[1] Stanford Canc Inst, Dept Radiat Oncol, Stanford, CA USA
[2] Stanford Univ, Dept Radiat Oncol, Sch Med, Stanford, CA 94305 USA
[3] UC Irvine, Sch Med, Irvine, CA USA
[4] Stanford Canc Inst, Dept Radiat Oncol, Indianapolis, IN USA
[5] Dept Radiat Oncol, Stanford, CA USA
关键词
D O I
10.1016/j.ijrobp.2019.06.151
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
1071
引用
收藏
页码:S148 / S148
页数:1
相关论文
共 50 条
  • [21] Stereotactic Ablative Radiotherapy (SABR) in Oligometastatic and Oligoprogressive Gynecologic Cancers: Clinical Outcomes of a Single Institution Analysis
    Donovan, E.
    Cheung, P.
    Erler, D.
    Davidson, M. T. M.
    Sahgal, A.
    Chung, H. T.
    Poon, I.
    Taggar, A.
    Barnes, E.
    Jerzak, K.
    Gien, L. T.
    Leung, E. W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E179 - E180
  • [22] Stereotactic ablative radiotherapy (SABR) for patients with lung tumor and severe pulmonary function impairment
    Geng-Cahuayme, Abraham Andre Arturo
    Peregrin-Pastor, Blanca
    Ramos-Albiac, Monica
    Recalde-Vizcay, Enar
    Parada-Zuluaga, Juan Sebastian
    de Sagredo, Jordi Giralt-Lopez
    Maldonado-Pijoan, Xavier
    Giraldo-Marin, Alexandra
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, : 3246 - 3251
  • [23] Time course and predictive factors for lung volume reduction following stereotactic ablative radiotherapy (SABR) of lung tumors
    Binkley, Michael S.
    Shrager, Joseph B.
    Chaudhuri, Aadel
    Popat, Rita
    Maxim, Peter G.
    Shultz, David Benjamin
    Diehn, Maximilian
    Loo, Billy W., Jr.
    RADIATION ONCOLOGY, 2016, 11
  • [24] Malignant lung nodules treated with Stereotactic Body Radiotherapy (SBRT): A single institution experience
    Borghetti, P.
    Maddalo, M.
    Vitali, P.
    Trevisan, F.
    Bonetti, B.
    Buglione, M.
    Pasinetti, N.
    Barbera, F.
    Magrini, S. M.
    RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S123 - S124
  • [25] Time course and predictive factors for lung volume reduction following stereotactic ablative radiotherapy (SABR) of lung tumors
    Michael S. Binkley
    Joseph B. Shrager
    Aadel Chaudhuri
    Rita Popat
    Peter G. Maxim
    David Benjamin Shultz
    Maximilian Diehn
    Billy W. Loo
    Radiation Oncology, 11
  • [26] Detection of Circulating Tumor DNA After Stereotactic Ablative Radiotherapy in Patients With Unbiopsied Lung Tumors (SABR-DETECT)
    Verma, Saurav
    Young, Sympascho
    Kennedy, Thomas A. C.
    Carvalhana, Ilda
    Black, Morgan
    Baer, Kathie
    Churchman, Emma
    Warner, Andrew
    Allan, Alison L.
    Izaguirre-Carbonell, Jesus
    Dhani, Harmeet
    Louie, Alexander, V
    Palma, David A.
    Breadner, Daniel A.
    CLINICAL LUNG CANCER, 2024, 25 (02) : e87 - e91
  • [27] Stereotactic ablative body radiotherapy for the treatment of oligometastases: a single-institution experience
    Murphy, G. A.
    Elbeltagi, M.
    LUNG CANCER, 2018, 115 : S57 - S58
  • [28] Stereotactic ablative radiotherapy (SABR) for early-stage central lung tumors: New insights and approaches
    Tekatli, H.
    Spoelstra, F. O. B.
    Palacios, M.
    de Koste, J. van Sornsen
    Slotman, B. J.
    Senan, S.
    LUNG CANCER, 2018, 123 : 142 - 148
  • [29] Central Lung Tumors Treated with Stereotactic Radiotherapy. Toxicity and Early Results in a Single Institution
    Nunez, M.
    Folgar, A.
    Diez, L.
    Gomez, R.
    Mur, E.
    Sole, J. M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S896 - S897
  • [30] Lung metastases from different primary tumors treated with Stereotactic ablative radiotherapy
    Rojas Cordero, J. V.
    Sancho Pardo, G.
    Majercakova, K.
    Gallego Franco, P.
    Carrasco de Fez, P.
    Soto Cambres, A. M.
    Balart Serra, J.
    Farre Bernado, N.
    RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S1057 - S1058